{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:37:59Z","timestamp":1780807079699,"version":"3.54.1"},"reference-count":82,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2016,7,29]]},"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Non-selective \u03b2-blockers (NSBBs) are widely prescribed in patients with cirrhosis for primary and secondary prophylaxis of bleeding oesophageal varices. Furthermore, it has been suggested that the clinical benefits of NSBBs may extend beyond their haemodynamic effects. Recently, a potentially harmful effect has been described in patients with refractory ascites or spontaneous bacterial peritonitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methodology<\/jats:title>\n                  <jats:p>A comprehensive literature search on \u03b2-blockers and cirrhosis survival using the electronic databases PubMed\/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts published over more than 35 years, from 1980 to April 2016 were reviewed for relevance and reference lists were cross-checked for additional pertinent studies regarding potential NSBB effects, especially focused on those concerned with survival and\/or acute kidney injury (AKI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The proposed review will be able to provide valuable evidence to help decision making in the use of NSBB for the treatment of advanced cirrhosis and highlights some limitations in existing evidence to direct future research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2016-000104","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T11:04:51Z","timestamp":1481281491000},"page":"e000104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Non-selective \u03b2-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function"],"prefix":"10.1136","volume":"3","author":[{"given":"Sara","family":"Blasco-Algora","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario Fundaci\u00f3n Alcorcon, Madrid, Spain"},{"name":"University Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Masegosa-Ataz","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario Fundaci\u00f3n Alcorcon, Madrid, Spain"},{"name":"University Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Alonso","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario Fundaci\u00f3n Alcorcon, Madrid, Spain"},{"name":"University Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luisa","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario Fundaci\u00f3n Alcorcon, Madrid, Spain"},{"name":"University Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Fern\u00e1ndez-Rodriguez","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario Fundaci\u00f3n Alcorcon, Madrid, Spain"},{"name":"University Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"2025073012551308000_3.1.e000104.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21089"},{"key":"2025073012551308000_3.1.e000104.2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.1.73"},{"key":"2025073012551308000_3.1.e000104.3","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007133"},{"key":"2025073012551308000_3.1.e000104.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-2-200807150-00007"},{"key":"2025073012551308000_3.1.e000104.5","first-page":"750","article-title":"Medical treatment of portal hypertension","volume":"20","author":"Lebrec","year":"1991","journal-title":"Presse Med"},{"key":"2025073012551308000_3.1.e000104.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191505"},{"key":"2025073012551308000_3.1.e000104.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0901512"},{"key":"2025073012551308000_3.1.e000104.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.013"},{"key":"2025073012551308000_3.1.e000104.9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.456"},{"key":"2025073012551308000_3.1.e000104.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02038.x"},{"key":"2025073012551308000_3.1.e000104.11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.12782","article-title":"Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"35","author":"Thiele","year":"2015","journal-title":"Liver Int"},{"key":"2025073012551308000_3.1.e000104.12","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50133"},{"issue":"1","key":"2025073012551308000_3.1.e000104.13","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jhep.2008.01.021","article-title":"The management of portal hypertension: rational basis, available treatments and future options","volume":"48","author":"Bosch","year":"2008","journal-title":"J Hepatol"},{"key":"2025073012551308000_3.1.e000104.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23852"},{"key":"2025073012551308000_3.1.e000104.15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301348"},{"key":"2025073012551308000_3.1.e000104.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044456"},{"key":"2025073012551308000_3.1.e000104.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"2025073012551308000_3.1.e000104.18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"key":"2025073012551308000_3.1.e000104.19","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50447"},{"key":"2025073012551308000_3.1.e000104.20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20766"},{"key":"2025073012551308000_3.1.e000104.21","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.180570"},{"key":"2025073012551308000_3.1.e000104.22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol\u2014a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet"},{"key":"2025073012551308000_3.1.e000104.23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","article-title":"Nonselective \u03b2-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis","volume":"14","author":"Chirapongsathorn","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073012551308000_3.1.e000104.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.10.028"},{"key":"2025073012551308000_3.1.e000104.25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i10.3100"},{"key":"2025073012551308000_3.1.e000104.26","doi-asserted-by":"crossref","unstructured":"Bhardwaj A , Kedarisetty CK , Vashishtha C , et al . Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2016; \u25aa\u25aa\u25aa doi:10.1136\/gutjnl-2016-311735","DOI":"10.1136\/gutjnl-2016-311735"},{"key":"2025073012551308000_3.1.e000104.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(01)80134-1"},{"key":"2025073012551308000_3.1.e000104.28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.019"},{"key":"2025073012551308000_3.1.e000104.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)80974-0"},{"key":"2025073012551308000_3.1.e000104.30","first-page":"2133","article-title":"Prognosis of patients with liver cirrhosis and spontaneous bacterial peritonitis","volume":"50","author":"Jepsen","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"2025073012551308000_3.1.e000104.31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"2025073012551308000_3.1.e000104.32","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(16)00298-1","article-title":"Use of non-selective beta blockers (NSBB) in cirrhotic patients with bacterial infections is associated with lower frequency of sepsis, but not of acute-on-chronic liver failure (ACLF) or survival. Results of a prospective study","volume":"64","author":"Pereira","year":"2016","journal-title":"J Hepatol"},{"key":"2025073012551308000_3.1.e000104.33","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80424-2"},{"key":"2025073012551308000_3.1.e000104.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.011"},{"key":"2025073012551308000_3.1.e000104.35","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.185413"},{"key":"2025073012551308000_3.1.e000104.36","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182784c93"},{"key":"2025073012551308000_3.1.e000104.37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fimmu.2015.00223","article-title":"Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability","volume":"6","author":"de Punder","year":"2015","journal-title":"Front Immunol"},{"key":"2025073012551308000_3.1.e000104.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.06.012"},{"key":"2025073012551308000_3.1.e000104.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.001"},{"key":"2025073012551308000_3.1.e000104.40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3748\/wjg.v12.i10.1493","article-title":"Gut flora and bacterial translocation in chronic liver disease","volume":"12","author":"Almeida","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025073012551308000_3.1.e000104.41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310109"},{"key":"2025073012551308000_3.1.e000104.42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4254\/wjh.v8.i9.421","article-title":"New advances in hepatocellular carcinoma","volume":"8","author":"Pascual","year":"2016","journal-title":"World J Hepatol"},{"key":"2025073012551308000_3.1.e000104.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61347-0"},{"key":"2025073012551308000_3.1.e000104.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404710"},{"key":"2025073012551308000_3.1.e000104.45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300779"},{"key":"2025073012551308000_3.1.e000104.46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.197"},{"key":"2025073012551308000_3.1.e000104.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2007.12.005"},{"key":"2025073012551308000_3.1.e000104.48","first-page":"1669","article-title":"The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappaB signaling","volume":"24","author":"Liao","year":"2010","journal-title":"Oncol Rep"},{"key":"2025073012551308000_3.1.e000104.49","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MEG.0000000000000677","article-title":"The use of \u03b2-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis","volume":"28","author":"Herrera","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025073012551308000_3.1.e000104.50","doi-asserted-by":"crossref","first-page":"11463","DOI":"10.3748\/wjg.v20.i32.11463","article-title":"Nonselective \u03b2-blockers may induce development of portal vein thrombosis in cirrhosis","volume":"20","author":"Qi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025073012551308000_3.1.e000104.51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27546"},{"key":"2025073012551308000_3.1.e000104.52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23775"},{"key":"2025073012551308000_3.1.e000104.53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23839"},{"key":"2025073012551308000_3.1.e000104.54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2014.03.040","article-title":"An apology for beta blockers","volume":"61","author":"Thalheimer","year":"2014","journal-title":"J Hepatol"},{"key":"2025073012551308000_3.1.e000104.55","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1002\/hep.24176","article-title":"Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?","volume":"53","author":"Senzolo","year":"2011","journal-title":"Hepatology"},{"key":"2025073012551308000_3.1.e000104.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(96)70068-9"},{"key":"2025073012551308000_3.1.e000104.57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0016-5085(94)90706-4","article-title":"Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites","volume":"106","author":"Pozzi","year":"1994","journal-title":"Gastroenterology"},{"key":"2025073012551308000_3.1.e000104.58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110420"},{"key":"2025073012551308000_3.1.e000104.59","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9247479"},{"key":"2025073012551308000_3.1.e000104.60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.15403\/jgld.2014.1121.233.apac","article-title":"Pathophysiological and clinical approach to cirrhotic cardiomyopathy","volume":"23","author":"Pall","year":"2014","journal-title":"J Gastrointest Liver Dis"},{"key":"2025073012551308000_3.1.e000104.61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrgastro.2013.210","article-title":"Cirrhotic cardiomyopathy: pathogenesis and clinical relevance","volume":"11","author":"Wiese","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025073012551308000_3.1.e000104.62","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9531-y"},{"key":"2025073012551308000_3.1.e000104.63","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9109-7"},{"key":"2025073012551308000_3.1.e000104.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2006.06.003"},{"key":"2025073012551308000_3.1.e000104.65","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10620-014-3432-8","article-title":"Recent advances in cirrhotic cardiomyopathy","volume":"60","author":"Karagiannakis","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2025073012551308000_3.1.e000104.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.034"},{"key":"2025073012551308000_3.1.e000104.67","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/hep.28575","article-title":"Propranolol use beyond 6 months increases mortality in patients with CPT C cirrhosis and ascites","volume":"64","author":"Kalambokis","year":"2016","journal-title":"Hepatology"},{"key":"2025073012551308000_3.1.e000104.68","first-page":"277A","article-title":"The effect of long-term use of nonselective beta-blocker on the development of acute kidney injury in patients with liver cirrhosis","volume":"60","author":"Kim","year":"2014","journal-title":"Hepatology"},{"key":"2025073012551308000_3.1.e000104.69","first-page":"66A","article-title":"North American Consortium for the Study of End-Stage Liver Disease. The association of non-selective beta-blocker use and acute kidney injury in patients with decompensated cirrhosis admitted into hospital\u2014a study from the North American Consortium for the Study of End Stage Liver Disease (NACSELD)","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology"},{"key":"2025073012551308000_3.1.e000104.70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.005"},{"key":"2025073012551308000_3.1.e000104.71","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306502"},{"key":"2025073012551308000_3.1.e000104.72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjms.2015.11.018","article-title":"The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites","volume":"351","author":"Aday","year":"2016","journal-title":"Am J Med Sci"},{"key":"2025073012551308000_3.1.e000104.73","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.948053"},{"key":"2025073012551308000_3.1.e000104.74","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26676"},{"key":"2025073012551308000_3.1.e000104.75","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients","volume":"63","author":"Bossen","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"2025073012551308000_3.1.e000104.76","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S0168-8278(16)00253-1","article-title":"Beta-blocker use in hospitalized cirrhotic patients with ascites is associated with a lower MELD, less inflammation and an improved survival","volume":"64","author":"Bhutta","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"2025073012551308000_3.1.e000104.77","doi-asserted-by":"crossref","first-page":"S668","DOI":"10.1016\/S0168-8278(16)01259-9","article-title":"Non-selective beta blockers (NSBBS) use is associated with improved survival in cirrhotic patients with ascites: a single centre retrospective study","volume":"64","author":"Onali","year":"2016","journal-title":"J Hepatol"},{"key":"2025073012551308000_3.1.e000104.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242202"},{"key":"2025073012551308000_3.1.e000104.79","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.giec.2015.03.001","article-title":"The role of medical therapy for variceal bleeding","volume":"25","author":"Bhutta","year":"2015","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"2025073012551308000_3.1.e000104.80","first-page":"CD004544","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","volume":"8","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2025073012551308000_3.1.e000104.81","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000171388","article-title":"Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment","volume":"10","author":"Pagliaro","year":"1992","journal-title":"Dig Dis"},{"key":"2025073012551308000_3.1.e000104.82","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S0168-8278(16)01678-0","article-title":"Prevalence of cardiomyopathy and impact of the use of non selective beta blockers in end-stage liver disease","volume":"64","author":"Giannelli","year":"2016","journal-title":"J Hepatol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2016-000104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:55:20Z","timestamp":1753905320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2016-000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,1]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1136\/bmjgast-2016-000104"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2016-000104","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}